Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/2d/44/3e/2d443ed5-5060-9ea4-317a-adaf90105d67/mza_1203040500825369576.jpg/600x600bb.jpg
Dr. GPCR Podcast
Dr. Yamina Berchiche
214 episodes
6 days ago
We bring you closer to dedicated scientists who work tirelessly to help understand GPCR pathophysiology.
Show more...
Life Sciences
Science
RSS
All content for Dr. GPCR Podcast is the property of Dr. Yamina Berchiche and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
We bring you closer to dedicated scientists who work tirelessly to help understand GPCR pathophysiology.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/3234728/3234728-1746122388561-5a09acc83334e.jpg
When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements / Dr.GPCR Podcast 166
Dr. GPCR Podcast
49 minutes 49 seconds
6 months ago
When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements / Dr.GPCR Podcast 166

Episode 166 of the Dr. GPCR Podcast features Benjamin Clements, a postdoctoral fellow at the University of Michigan, who brings fresh insight into the therapeutic promise of GPCRs — particularly in the context of opioid pharmacology. With a background in pharmaceutical sciences and neuroscience, Ben now focuses on positive allosteric modulators (PAMs) targeting the mu-opioid receptor, aiming to preserve opioid analgesia while reducing harmful side effects like respiratory depression and addiction.In this episode, Ben and Dr. Yamina Berchiche discuss how a passion for translational science led him to investigate chronic pain models, including neuromas, where opioids traditionally fail. His lab’s preliminary findings — including a tenfold improvement in methadone efficacy — highlight the potential of GPCR-targeted allosteric modulators to change the treatment landscape for intractable pain conditions. These discoveries are the result of collaborative, curiosity-driven science in a lab culture that values both rigor and levity.Ben also shares his perspective on learning “old-school” assays like radioligand binding and GTPγS, emphasizing their enduring value even amid advanced high-throughput techniques. The conversation touches on mentorship, imposter syndrome, and the critical importance of creating space for new voices in the GPCR field. As Ben puts it:“Academia is all about knowing when to walk and when to run.”This episode is a powerful reminder of the role that early-career scientists play in shaping the future of GPCR drug discovery — blending pharmacological fundamentals with bold experimentation and a deep commitment to patient-centered science.Watch the complete episode at: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-166-with-ben-clements


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.

  • Premium Yearly
  • Premium Yearly for Teams
  • Developing Countries


Are you a #GPCR professional?


  • Subscribe to the Classified GPCR Weekly News
  • Listen and subscribe to #DrGPCRPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠
Dr. GPCR Podcast
We bring you closer to dedicated scientists who work tirelessly to help understand GPCR pathophysiology.